Erratum: Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma Anti–vascular endothelial growth factor therapy enhances PD-1 ...
ASCO Journals have adopted a format-free submission policy (EZSubmit). New submissions are not scrutinized for compliance with our formatting guidelines (reference style, order of components, figure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback